Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011582 | 0.98 | KMT2A (0.63) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL9448931 | 0.86 | KMT2A (0.62) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL9448933 | 0.86 | KMT2A (0.62) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL10773171 | 0.83 | KMT2A (0.58) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL7043903 | 0.83 | KMT2A (0.58) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL23409168 | 0.81 | RAB9A (0.46) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL1516027 | 0.81 | MMP8 (0.53) | KMT2AMEN1LMNATSHR | |
| SCHEMBL31726783 | 0.81 | KMT2A (0.43) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL27964745 | 0.81 | L3MBTL1 (0.47) | KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL15020603 | 0.81 | KMT2A (0.47) | KMT2AMEN1PTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396160-B | Method for preparing tropine acid and method for preparing atropine sulfate by using tropine acid | 烟台万润药业有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-115754042-B | Method for detecting impurity alpha-formylphenyl methyl acetate in ipratropium bromide | 石家庄四药有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-115754042-A | Method for detecting impurity alpha-formyl methyl phenylacetate in ipratropium bromide | 石家庄四药有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-105985241-A | Inhibition effect of [alpha]-substituted phenyl acetate compounds on [alpha]-glycosidase and application of the compounds | 邵阳学院 | 2016-10-05 | — | — | CN | claimed |
| US-20260040820-A1 | PHENANTHROLINE COMPOUND, AND ORGANIC THIN FILM AND ORGANIC SEMICONDUCTOR ELEMENT USING SAME | NIPPON CATALYTIC CHEM IND (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4622958-A1 | SYNTHESIS OF PYRROLO[3,4-C]PYRROLES | Novo Nordisk Health Care AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4619376-A2 | CYCLIC DESIGNER SCAFFOLDS FOR THE COVALENT TARGETING OF PROTEINS VIA MICHAEL ADDITION | Protenic Fejleszto Es Szolgaltato Kft. (HU) | 2025-09-24 | — | — | EP | disclosed |
| CN-115572290-B | Method for synthesizing ipratropium bromide by one-pot method | 河北仁合益康药业有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024112764-A1 | SYNTHESIS OF PYRROLO[3,4-C]PYRROLES | NOVO NORDISK HEALTH CARE AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024105420-A2 | CYCLIC DESIGNER SCAFFOLDS FOR THE COVALENT TARGETING OF PROTEINS VIA MICHAEL ADDITION | Természettudományi Kutatóközpont (HU) | 2024-05-23 | — | — | WO | disclosed |
| CN-1144475-A | Polyamino salts of alpha-hydroxyacids, alpha-ketoacids and related compounds | UNILEVER PLC (NL) | 1997-03-05 | — | — | CN | disclosed |
| US-5574153-A | BACTERICIDES | ACS DOBFAR S.P.A. (IT) | 1996-11-12 | — | — | US | disclosed |
| EP-0638574-A1 | Oxime derivatives of cephalosporanic structure and compounds for their preparation | ACS DOBFAR S.p.A. (IT) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994006737-A1 | PROCESS FOR PREPARING FELBAMATE, 2-PHENYL-1,3-PROPANEDIOL AND INTERMEDIATES | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0588652-A1 | Process for the preparation of 2-aryl-1,3-propanediols | GANES CHEMICALS INC. (US) | 1994-03-23 | — | — | EP | disclosed |
| US-4997955-A | From aldehyde | BASF AKTIENGESELLSCHAFT (DE) | 1991-03-05 | — | — | US | disclosed |
| EP-0132987-B1 | IMPROVEMENTS IN OR RELATING TO DEESTERIFICATION TO ACIDS | ELI LILLY AND COMPANY (US) | 1987-09-16 | — | — | EP | disclosed |
| EP-0132987-A1 | Improvements in or relating to deesterification to acids | ELI LILLY AND COMPANY (US) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260040820-A1 | PHENANTHROLINE COMPOUND, AND ORGANIC THIN FILM AND ORGANIC SEMICONDUCTOR ELEMENT USING SAME | AHR, PAH, PROX1 | KMT2A 1112/4885MEN1 1870/4885PTGS1 2871/4885 |
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | KMT2A 4484/4885MEN1 290/4885PTGS1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.